(Q47805747)

5 February 2018

title

Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation (English)

1 reference

5 February 2018

0 references

1

Amy Barton Pai

1 reference

5 February 2018

language of work or name

English

0 references

publication date

13 October 2017

1 reference

5 February 2018

Annals of the New York Academy of Sciences

published in

1 reference

5 February 2018

volume

1407

1 reference

5 February 2018

issue

1

1 reference

5 February 2018

page(s)

17-25

1 reference

5 February 2018

The initial impact of Medicare's new prospective payment system for kidney dialysis

cites work

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Considerations and challenges in defining optimal iron utilization in hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Nanomedicine(s) under the microscope

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Toxic effects of iron oxide nanoparticles on human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Co-precipitation of DEAE-dextran coated SPIONs: how synthesis conditions affect particle properties, stem cell labelling and MR contrast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Thermodynamic stability assessment of a colloidal iron drug product: sodium ferric gluconate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Nitrosative stress and apoptosis in non-anemic healthy rats induced by intravenous iron sucrose similars versus iron sucrose originator

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Labile iron in cells and body fluids: physiology, pathology, and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Physicochemical properties of ferumoxytol, a new intravenous iron preparation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Clinical and research markers of oxidative stress in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Iron toxicity: relevance for dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Administration of parenteral iron and mortality among hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Comparative Short-term Safety of Sodium Ferric Gluconate Versus Iron Sucrose in Hemodialysis Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Scientific and Regulatory Considerations for Generic Complex Drug Products Containing Nanomaterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

The Labile Side of Iron Supplementation in CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Innovative approaches for demonstration of bioequivalence: the US FDA perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Medication practice in hospitals: are nanosimilars evaluated and substituted correctly?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Differences in tissue distribution of iron from various clinically used intravenous iron complexes in fetal avian heart and liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Do two intravenous iron sucrose preparations have the same efficacy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.13461

21 January 2018

Identifiers

DOI

10.1111/NYAS.13461

1 reference

5 February 2018

1 reference

5 February 2018